Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 375

1.

[Recombinant factor VIIa (NovoSeven). A review of current and possible future indications].

Heuer L, Blumenberg D.

Anaesthesist. 2002 May;51(5):388-99. Review. German.

PMID:
12125311
2.

[Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].

Levi M, Friederich PW, van der Meer J.

Ned Tijdschr Geneeskd. 2002 Dec 28;146(52):2534-7. Review. Dutch.

PMID:
12532665
3.

Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?

Brackmann HH, Effenberger W, Hess L, Schwaab R, Oldenburg J.

Eur J Haematol Suppl. 1998;63:18-23. Review.

PMID:
9882928
4.
5.

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.

Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E.

Thromb Haemost. 1998 Dec;80(6):912-8.

PMID:
9869160
6.

NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds.

Rice KM, Savidge GF.

Haemostasis. 1996;26 Suppl 1:131-4.

PMID:
8904187
7.

Recombinant factor VIIa.

Aitken MG.

Emerg Med Australas. 2004 Oct-Dec;16(5-6):446-55. Review.

PMID:
15537408
8.
9.

Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.

Brady KM, Easley RB, Tobias JD.

Paediatr Anaesth. 2006 Oct;16(10):1042-6.

PMID:
16972833
10.

Recombinant factor VIIa in joint and muscle bleeding episodes.

Bech RM.

Haemostasis. 1996;26 Suppl 1:135-8.

PMID:
8904188
11.

Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.

Chuansumrit A, Isarangkura P, Angchaisuksiri P, Sriudomporn N, Tanpowpong K, Hathirat P, Jorgensen LN.

Haemophilia. 2000 Mar;6(2):61-5.

PMID:
10781189
12.

Approaches towards successful home treatment in patients with inhibitors.

Ingerslev J, Thykjaer H, Scheibel E.

Eur J Haematol Suppl. 1998;63:11-4.

PMID:
9882926
14.

Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use.

Nicolaisen EM, Hansen LL, Poulsen F, Glazer S, Hedner U.

Thromb Haemost. 1996 Aug;76(2):200-4.

PMID:
8865531
15.

The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage.

Franchini M, Lippi G, Franchi M.

BJOG. 2007 Jan;114(1):8-15. Review.

16.

The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework.

Moltzan CJ, Anderson DA, Callum J, Fremes S, Hume H, Mazer CD, Poon MC, Rivard G, Rizoli S, Robinson S.

Transfus Med. 2008 Apr;18(2):112-20. doi: 10.1111/j.1365-3148.2008.00846.x.

PMID:
18399845
17.

Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.

Petrini P, Klementz G.

Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S143-6.

PMID:
9819046
18.

Clinical experience with activated factor VII: focus on safety aspects.

Roberts HR.

Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S115-8.

PMID:
9819041
20.

The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.

Rizoli SB, Chughtai T.

Expert Opin Biol Ther. 2006 Jan;6(1):73-81. Review.

PMID:
16370916

Supplemental Content

Support Center